GBA1 and Parkinson disease: Ambroxol has been demonstrated to enhance the activity of GCase and decrease GCase substrates in GBA1-mutated macrophages, and it can penetrate the brain, resulting in higher GCase levels in the cerebrospinal fluid of patients with PD carrying (or not) GBA1 mutations [48].